Mounjaro drugs: understanding tirzepatide and your options

What kind of drug is Mounjaro, and why does the dual mechanism matter?

Most people researching weight-loss drugs will come across the term GLP-1 receptor agonist. Mounjaro is that, but it goes one step further. Tirzepatide, the active molecule inside every Mounjaro KwikPen, also activates the GIP receptor, a second gut-hormone pathway involved in appetite regulation and blood-sugar control. No other weight-loss drug licensed in the UK does this. That distinction is not marketing language; it is the reason researchers think tirzepatide produces greater average weight loss than semaglutide, its closest comparison, as the SURMOUNT-5 head-to-head trial published in the New England Journal of Medicine in 2025 showed.

The practical effect is that most people on tirzepatide feel meaningfully less hungry, eat smaller portions without effort, and slow the rate at which food leaves their stomach. The drug works alongside reduced-calorie eating and increased activity, not instead of them. If you want a broader look at how GLP-1 drugs like Mounjaro fit into weight management, that page covers the mechanism in more depth. For now, the key point is that the dual pathway is the reason tirzepatide sits at the head of the current evidence.

Because Mounjaro is a Black Triangle medicine, the MHRA continues to collect safety data from real-world use. That is standard for newer drugs and does not signal concern, it signals rigour. Patients and clinicians can report any unexpected side effects via the MHRA Yellow Card scheme, which also accepts reports of suspect sellers.

Who is this drug suitable for, and where does eligibility sit?

The licensed criteria for Mounjaro in the UK are a BMI of 30 or above, or a BMI of 27 or above alongside at least one weight-related health condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance. Those criteria define who the drug is designed for, but eligibility does not end with a BMI number. A prescriber reviews the whole picture: your medical history, current medicines, and any contraindications.

Mounjaro is not licensed for use in pregnancy, breastfeeding, or by anyone trying to conceive. It is also not licensed for under-18s. A personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 would also need careful prescriber discussion. The tirzepatide eligibility page goes into the full contraindication list in plain language.

On the NHS, access follows a phased rollout under NICE's appraisal of tirzepatide (TA1026), which sets stricter criteria than the licensed minimum, starting with the highest BMI and most comorbidities, then widening over time. Private prescribing through a regulated pharmacy applies the licensed criteria, subject to the individual prescriber's clinical judgement. The two routes differ in waiting time and criteria; neither bypasses clinical assessment.

What are the drugs most people compare Mounjaro with?

The honest answer is that most comparisons come down to tirzepatide versus semaglutide (Wegovy). Both are injectable, once-weekly prescription drugs. Both slow gastric emptying and reduce appetite. The difference is the dual mechanism described above and, in the trial data, a somewhat larger average weight loss for tirzepatide. Comparing Mounjaro with similar drugs in more detail (including how the evidence stacks up dose for dose) is worth doing before you commit to either.

Some people also ask about drugs like Ozempic. Ozempic contains semaglutide, but it is licensed in the UK for type 2 diabetes, not weight loss. It should not be presented or prescribed as a weight-loss drug; that distinction matters both clinically and legally. The only semaglutide products licensed for weight management in the UK are Wegovy (injection) and, as of June 2026, the new Wegovy tablet.

For many people, the decision also touches on how the drug fits daily routine. If you are also considering how other tirzepatide drugs compare in terms of formulation and licensing, that page sets out the options clearly. The Mounjaro pen lives in the fridge (the door shelf works fine) and comes out once a week for a quick subcutaneous injection. That regularity suits a lot of patients; for those who strongly prefer a tablet, the newer oral option is worth exploring. Weight-loss drugs and Mounjaro's place in the landscape covers the full comparison if you want context before your consultation.

Side effects, what to watch for, and how a prescriber supports you

The most commonly reported side effects with tirzepatide are gastrointestinal: nausea, loose stools, constipation, indigestion, and occasional burping. These tend to be most noticeable at the start of treatment or after a dose increase, and most people find they ease within a week or two as the body adjusts. Starting at 2.5 mg (the lowest dose in the licensed schedule) is specifically designed to minimise early GI discomfort before the prescriber considers moving up.

Pancreatitis is a less common but serious risk with GLP-1 class drugs. Severe stomach pain that radiates to the back, especially if it persists or comes with vomiting, needs urgent medical attention rather than waiting to see if it settles. The NHS tirzepatide medicines page lists the full side-effect profile alongside clear advice on when to seek help.

Other points worth knowing: if you are on oral contraceptives, you should discuss adding a barrier method during the first four weeks of treatment and after each dose increase, because tirzepatide's effect on gastric emptying may reduce pill absorption. The same goes for oral HRT, transdermal alternatives are worth considering. If you are wondering about recreational substances, our page on Mounjaro and MDMA explains the interaction risks in straightforward terms. Our clinical team can walk through any of this during your consultation.

A prescriber also reviews your case before every repeat order at nume, not just the first time. Questions about whether a drug like this is right for you, or how it compares with your current approach, are also a good starting point on the FAQs page. If you are ready to take the next step, start your free consultation with our prescribers today.